Innovotech reports Q2 2026 loss amid lower revenue, invests in growth and new testing kits launch

Innovotech Inc. reported a net loss of $655,700 for Q2 2026, with revenue down to $679,841 from $984,327 in Q2 2025. The company is addressing challenges by improving cash management, resizing operations, and investing in new technology, including a MALDI-TOF system and cleanroom upgrades. Post-quarter, Innovotech launched InnovoTEST™ Hazardous Drug Wipe Testing Kits to expand its healthcare service offerings. These steps aim to diversify its customer base and position the company for future growth despite current financial setbacks.